International Myeloma Society (IMS) Practical Insights in and Translational Aspects of Novel Immune Therapies in Multiple Myeloma 2025 (Videos)

Comprehensive Updates in CAR T-Cell Therapy, Bispecific Antibodies, Antibody-Drug Conjugates, BCMA-Targeted Therapies, and Precision Immunotherapy for Multiple Myeloma

Advance your understanding of next-generation immunotherapy with the International Myeloma Society (IMS) Practical Insights in and Translational Aspects of Novel Immune Therapies in Multiple Myeloma 2025, an advanced continuing medical education (CME) program dedicated to the rapidly evolving landscape of immune-based treatments for multiple myeloma. This comprehensive educational workshop provides clinicians with practical guidance for integrating novel immunotherapies into clinical practice while addressing patient selection, toxicity management, translational science, and real-world treatment strategies.

Held on October 27, 2025, in conjunction with the DGHO Annual Meeting, the program is offered both virtually and in person at the Congress-Centrum Koelnmesse in Cologne, Germany. International experts review the latest clinical evidence supporting antibody-drug conjugates (ADCs), bispecific T-cell engagers (TCEs), and chimeric antigen receptor (CAR) T-cell therapies, with particular emphasis on B-cell maturation antigen (BCMA)-targeted treatments for patients with relapsed or refractory multiple myeloma.

Designed to bridge the educational gap between specialized CAR T treatment centers and community oncology practices, this workshop equips healthcare professionals with practical, evidence-based approaches for implementing advanced immune therapies while optimizing patient safety and treatment outcomes.

Product Details

• Course: Practical Insights in and Translational Aspects of Novel Immune Therapies in Multiple Myeloma 2025
• Provider: International Myeloma Society (IMS)
• Conference Date: October 27, 2025
• Location: Congress-Centrum Koelnmesse, Cologne, Germany
• Format: Hybrid (In-Person & Virtual) – Videos
• Language: English
• Educational Level: Advanced

Course Overview

The treatment landscape for multiple myeloma has undergone remarkable transformation with the introduction of highly effective immune-based therapies. Novel agents targeting BCMA, including CAR T-cell therapies, bispecific antibodies, and antibody-drug conjugates, have significantly improved outcomes for patients with relapsed or refractory disease while introducing new challenges related to patient selection, toxicity management, supportive care, and treatment sequencing.

This comprehensive educational program provides clinicians with practical guidance for incorporating these innovative therapies into everyday oncology practice. Faculty review current clinical trial data, translational research, mechanisms of immune activation, treatment eligibility, adverse event recognition, and multidisciplinary patient management strategies.

Participants gain a practical understanding of how novel immune therapies are reshaping the management of multiple myeloma while learning evidence-based approaches that can be applied across both academic and community oncology settings.

What You’ll Learn

After completing this course, participants will be able to:

• Identify patients who are appropriate candidates for CAR T-cell therapy and bispecific antibody treatment.
• Differentiate the mechanisms of action of CAR T cells, bispecific T-cell engagers, and antibody-drug conjugates.
• Apply evidence-based strategies for selecting immune-based therapies in relapsed and refractory multiple myeloma.
• Recognize and manage treatment-related toxicities associated with novel immunotherapies.
• Integrate BCMA-targeted therapies into individualized treatment plans.
• Improve coordination between referral centers and community oncology practices.
• Apply translational research findings to optimize patient outcomes.

Comprehensive Topics Covered

Multiple Myeloma Immunotherapy

Review the latest advances in immune-based treatment strategies that are transforming the management of multiple myeloma.

Topics include:

• Immune therapies
• Precision oncology
• Personalized treatment
• Treatment sequencing
• Clinical decision-making
• Emerging therapeutic strategies

CAR T-Cell Therapy

Develop a comprehensive understanding of CAR T-cell therapy from patient referral through treatment and long-term follow-up.

Topics include:

• CAR T-cell manufacturing
• Patient eligibility
• Treatment preparation
• Clinical outcomes
• Long-term monitoring
• Response assessment

Faculty discuss practical implementation strategies for both referral and treatment centers.

Bispecific T-Cell Engagers (TCEs)

Review current evidence supporting bispecific antibodies and their growing role in relapsed and refractory multiple myeloma.

Topics include:

• T-cell engagers
• Mechanisms of action
• Clinical trial updates
• Patient selection
• Treatment sequencing
• Response evaluation

Antibody-Drug Conjugates (ADCs)

Learn how antibody-drug conjugates are incorporated into modern myeloma treatment algorithms.

Topics include:

• Antibody-drug conjugates
• BCMA-targeted therapies
• Clinical efficacy
• Safety monitoring
• Adverse event management
• Patient selection

BCMA-Targeted Therapies

Explore the expanding role of B-cell maturation antigen (BCMA) as one of the most important therapeutic targets in modern multiple myeloma treatment.

Faculty review:

• BCMA biology
• Targeted immunotherapy
• Clinical applications
• Resistance mechanisms
• Future therapeutic developments

Toxicity Management

Gain practical strategies for recognizing, monitoring, and managing adverse events associated with advanced immune therapies.

Topics include:

• Cytokine release syndrome (CRS)
• Immune-related toxicities
• Neurotoxicity
• Infection prevention
• Supportive care
• Post-treatment monitoring

Translational Medicine

Bridge laboratory discoveries with clinical practice through expert discussions of translational research and future therapeutic developments.

Topics include:

• Translational oncology
• Biomarker development
• Immune microenvironment
• Precision medicine
• Future clinical trials

Community Oncology Integration

Learn practical approaches for improving collaboration between specialized cellular therapy centers and community oncology practices to ensure timely referral, appropriate patient selection, and continuity of care.

Learning Objectives

Upon completion of this educational activity, participants will be able to:

• Identify patients who may benefit from novel immune-based therapies.
• Differentiate CAR T-cell therapies, bispecific T-cell engagers, and antibody-drug conjugates.
• Apply evidence-based treatment selection strategies for relapsed and refractory multiple myeloma.
• Recognize and manage treatment-related toxicities associated with immune therapies.
• Integrate BCMA-targeted therapies into multidisciplinary patient care.
• Apply translational research findings to improve treatment outcomes.

Educational Highlights

• Multiple Myeloma
• CAR T-Cell Therapy
• BCMA-Targeted Therapy
• Bispecific Antibodies
• Bispecific T-Cell Engagers
• Antibody-Drug Conjugates
• Immunotherapy
• Cellular Therapy
• Translational Medicine
• Precision Oncology
• Hematologic Malignancies
• Plasma Cell Disorders
• Toxicity Management
• Cytokine Release Syndrome
• Neurotoxicity
• Supportive Care
• Community Oncology
• Case-Based Learning
• Expert Faculty
• Continuing Medical Education (CME)

Why This Course Stands Out

The International Myeloma Society Practical Insights in and Translational Aspects of Novel Immune Therapies in Multiple Myeloma 2025 provides one of the most practical educational updates available on modern immune-based treatment strategies for multiple myeloma. Rather than focusing exclusively on clinical trial data, the program emphasizes real-world implementation of CAR T-cell therapy, bispecific antibodies, and antibody-drug conjugates, helping clinicians confidently integrate these rapidly evolving therapies into routine patient care while effectively managing associated toxicities.

Target Audience

This educational activity is ideal for:

• Hematologists
• Medical Oncologists
• Hematopathologists
• Surgical Pathologists
• Infectious Disease Specialists
• Ophthalmologists
• Neurologists
• Immunologists
• Hematology Fellows
• Oncology Fellows
• Nurse Practitioners
• Physician Assistants
• Healthcare Professionals involved in the treatment of multiple myeloma and plasma cell disorders

Why Choose This Course?

Whether you practice hematology, medical oncology, pathology, or immunology, the International Myeloma Society Practical Insights in and Translational Aspects of Novel Immune Therapies in Multiple Myeloma 2025 delivers an exceptional evidence-based review of the latest immune therapies transforming multiple myeloma treatment. Combining internationally recognized faculty, translational science, practical treatment strategies, toxicity management, and multidisciplinary care, this program provides clinicians with the knowledge needed to confidently implement next-generation immunotherapies in modern clinical practice.

Topics

• Advances in Diagnostics

  • Breakout Lesions/EMD

  • Single Cell Spatial Organization of Tumor Microenvironment

  • Advances in MRD Detection: Peripheral Blood and Bone Marrow Strategies

  • Monitoring for Infectious Post-T-Cell-Based Therapy

  • Predictors of Response and Mechanisms of Relapse

• Treatment with Novel Agents/Novel Combinations/Novel Concepts

  • CelMOD (Combinations)

  • 1 Line Therapy with Belamaf + Future Options

  • 2 Line Therapy with Belamaf/Occular Management

  • Bispecific Combinations/Trispecifics

  • CART Cells in Earlier Lines

• Management of Complications

  • CIDP Post-Cilta-cel

  • Immune Effector Cell Associated Secondary Malignancies

  • Bridging Therapies

  • Relapse Management

  • Modulation of the Target Antigen